Picture of Extendicare logo

EXE — Extendicare News Story

0.000.00%
ca flag iconLast trade - 00:00
HealthcareBalancedMid CapHigh Flyer

Canada's Extendicare Q2 revenue misses estimates

Overview

Extendicare Q2 revenue rises 11.4% but misses analyst expectations

Adjusted EBITDA grows 15.4% to C$39.8 mln, driven by home health care

Net earnings increase by C$6.0 mln to C$31.9 mln in Q2

Outlook

Extendicare anticipates Q3 impact from Closing the Gap acquisition

Company expects Ontario LTC funding policy to support redevelopment

Extendicare sees increased liquidity from C$375 mln credit facility

Result Drivers

HOME HEALTH CARE GROWTH - Home health care average daily volume increased by 10.9%, driving revenue growth

LTC ACQUISITION - Acquisition of nine Class C LTC homes from Revera contributed to revenue and NOI growth

Key Details

MetricBeat/MissActualConsensus Estimate
Q2 RevenueMissC$383.44 mlnC$385.70 mln (3 Analysts)
Q2 Net IncomeC$31.93 mln
Q2 Adjusted EBITDAC$39.78 mln
Q2 Adjusted FFOC$24.78 mln
Q2 Adjusted EBITDA Margin10.4%
Q2 Operating ExpensesC$328.47 mln
Analyst Coverage The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell" The average consensus recommendation for the healthcare facilities & services peer group is "buy" Wall Street's median 12-month price target for Extendicare Inc is C$15.40, about 17.8% above its August 6 closing price of C$12.66 The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 18 three months ago Press Release: ID:nGNXc2sCJk (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Extendicare

See all news